SCHEMBL4155141

SCHEMBL4155141

CCOC(=O)c1cnc2c(F)cccc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 1/20 0.50
MAOB P27338 4/20 0.46
CYP1A2 P05177 1/20 0.45
NR1H4 Q96RI1 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 4/20 0.44
RAB9A P51151 3/20 0.44
MEN1 O00255 2/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGDS O60760 1/20 0.43
CA12 O43570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17502544 0.86 HPGDS (0.45) PSMD14MAOBNR1H4MAPTKMT2A
SCHEMBL2201187 0.85 KDM4E (0.55) PSMD14MAOBCYP1A2NR1H4MAPT
SCHEMBL2203246 0.85 PSMD14 (0.51) PSMD14MAOBCYP1A2NR1H4CYP2C9
SCHEMBL28234393 0.84 MAPT (0.51) PSMD14MAOBCYP1A2NR1H4MAPT
SCHEMBL7220371 0.84 MAOB (0.48) PSMD14MAOBMAPTCYP2C9CYP2C19
SCHEMBL4150906 0.84 MAOB (0.53) PSMD14MAOBCYP1A2NR1H4MAPT
SCHEMBL6537724 0.84 PSMD14 (0.50) PSMD14MAOBCYP1A2NR1H4MAPT
SCHEMBL4721861 0.83 HPGDS (0.64) PSMD14MAOBKMT2AMEN1HPGDS
SCHEMBL17375830 0.81 KMT2A (0.62) PSMD14MAOBMAPTKMT2ARAB9A
SCHEMBL27773938 0.81 CCR1 (0.54) PSMD14MAOBMAPTCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 US disclosed
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 US disclosed
WO-2014066506-A2 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-05-01 WO disclosed
WO-2012158435-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION ZHOU HAN-JIE (US) 2012-11-22 WO disclosed
US-20090186918-A1 Triazole Compounds as Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2009-07-23 US disclosed
EP-1943234-A1 TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS Biolipox AB (SE) 2008-07-16 EP disclosed
WO-2007051982-A1 TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS BIOLIPOX AB (SE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION USP24, USP36, USP39 PSMD14 7/4885MAOB 4008/4885CYP1A2 4481/4885
US-20090186918-A1 Triazole Compounds as Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 PSMD14 3868/4885MAOB 195/4885CYP1A2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.